Christoph Nitsche

Christoph Nitsche is an Associate Professor and ARC Future Fellow at the Research School of Chemistry, Australian National University (ANU). His research focuses on developing chemical tools to target, manipulate and study peptides and proteins related to infectious diseases. He leads the Nitsche Group, which applies interdisciplinary approaches spanning organic chemistry to structural biology to address questions of biological and medicinal relevance.

Dr. Nitsche completed his chemistry education with a Dipl.-Chem. from Halle, Germany, followed by an MBA from the University of Wales, UK, and a PhD from Heidelberg University, Germany in 2014. His doctoral work earned him the PhD Prize for Medicinal Chemistry by the German Chemical Society. He then received a prestigious Feodor Lynen Research Fellowship to conduct research at ANU from 2015-2018, followed by a Rising Star Fellowship at the Free University of Berlin. In 2019, he returned to ANU with an ARC Discovery Early Career Researcher Award (DECRA), was appointed Senior Lecturer in 2020, and promoted to Associate Professor in 2023. He currently holds an ARC Future Fellowship (2022-2027).

His research interests center on creating selective interactions between proteins and small synthetic molecules, with particular focus on:

• Developing next-generation peptide and protein drug candidates for infectious diseases
• Designing protease inhibitors for viral targets including SARS-CoV-2, dengue, and Zika viruses
• Innovating biocompatible synthetic routes to constrained peptides
• Exploring boronic acids as potential therapeutics
• Establishing novel chemical ligation reactions that function in biological systems
• Accelerating drug discovery through new technology platforms

Dr. Nitsche's recent publications demonstrate a strong trend toward developing peptide-based therapeutics with enhanced stability and specificity. His work frequently combines organic chemistry with structural biology to create innovative solutions for challenging drug targets, particularly viral proteases. A significant portion of his recent research focuses on constrained peptides, including bicyclic structures and bismuth-stabilized configurations, which show promise as next-generation pharmaceuticals with improved pharmacological properties.

Scientific Awards and Recognition

• ARC Future Fellowship (2022-2027)
• RACI Rennie Memorial Medal (2023)
• RSC Medicinal Chemistry Emerging Investigator Lectureship (2023)
• Thieme Chemistry Journals Award (2023)
• Peter Schwerdtfeger Award by the Australian Association of von Humboldt Fellows (2022)
• Australian Peptide Association John Wade Early Career Researcher Award (2022)
• ARC DECRA (2019)
• PhD Prize for Medicinal Chemistry by the German Chemical Society (2015)
• Feodor Lynen Research Fellowship by the Alexander von Humboldt Foundation (2015)
• Vice-Chancellor's Award for Excellence in Advancing Research (2023)
• American Peptide Society Lab of the Month (September 2024)
• Named top researcher in Medicinal Chemistry by 'The Australian' for 2023, 2024, and 2025

Dr. Nitsche actively supervises a research group comprising multiple PhD students and postdoctoral researchers. His current projects include developing biocompatible synthesis of bicyclic peptides, boronic acids as potential therapeutics for dengue fever, genetically encoded bicyclic peptides, inhibitors of the SARS-CoV-2 main protease, modular fluorescent tags, and broad-spectrum inhibitors of viral proteases. His research is supported by multiple grants including an ARC Future Fellowship project "Time to shine for constrained peptides as next-generation pharmaceuticals" (2023-2027) and collaborative projects on non-canonical amino acids for protein analysis and peptide inhibitors.

The Nitsche Group operates as a dynamic, interdisciplinary research team that bridges traditional boundaries between organic, inorganic and biological chemistry. They maintain state-of-the-art facilities for peptide synthesis, protein characterization, and drug discovery, contributing to ANU's reputation as a leading institution in medicinal chemistry research.